Porownywarka

Hexarelin vs GHRP-6 side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

HexarelinGHRP-6

Udostępnij porównanie peptydów

Wlasciwosc	Hexarelin	GHRP-6
Kategoria	Hormon wzrostu	Hormon wzrostu
Znany tez jako	Examorelin, HEX	Growth Hormone Releasing Peptide 6, SKF-110679
Zatwierdzony przez FDA	Nie	Nie
Status kliniczny	Investigational; clinical trials conducted Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	Preclinical/investigational; source notes FDA Category 2 compounding restriction concerns Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	GH release, cardiac protection, muscle growth	Appetite stimulation, muscle building, GH release
Jak dziala	Hexarelin is reported to work through GHS-R1a and CD36. GHS-R1a, also known as the ghrelin receptor, is the pituitary-linked pathway associated with growth hormone release. CD36 is described in the source as a receptor present on cardiac muscle cells and small blood vessels; preclinical work links this pathway to coronary-flow changes and protection from ischemia-reperfusion injury. The source notes that cardiac effects were still seen in growth-hormone-deficient animals, suggesting the cardiac mechanism is not simply downstream of growth hormone release.	GHRP-6 is reported to act as an agonist at GHS-R1a, the growth hormone secretagogue receptor associated with ghrelin biology. The source links receptor activation in pituitary and hypothalamic pathways to growth hormone pulse release. It also notes that GHS-R1a involvement in NPY/AgRP appetite circuitry may contribute to GHRP-6's prominent hunger effect, and that higher doses may raise cortisol and prolactin.
Typowe dawkowanie	100-200 mcg 2-3x daily · 2-3x daily	100-300 mcg 2-3x daily · 2-3x daily · Subcutaneous injection
Dawkowanie z badań	100-200 mcg per injection · 4-8 weeks (desensitization occurs) · Subcutaneous injection	100-300 mcg per injection · 8-12 weeks · Subcutaneous injection, reported as fasted
Typowy czas trwania	4-8 weeks (desensitization occurs)	8-12 weeks
Podanie	Subcutaneous injection	Subcutaneous injection, reported with fasted timing
Timing	Morning and before bed, fasted Empty stomach	Reported timing: fasted morning use or before bed Source reports empty-stomach or fasted timing
Poziom dowodów	Badania kliniczne	Badania kliniczne
Mozliwe skutki uboczne	Increased appetite Water retention Tingling or numbness +5 więcej Elevated cortisol and prolactin Flushing Headache May trigger histamine release (Source advises caution with MCAS or histamine sensitivity.) Receptor desensitization with continuous use (Source notes desensitization and fading GH response with continued use.)	Significant hunger increase (Source describes this as especially pronounced among GHRPs.) Water retention (Reported by source; severity not quantified.) Elevated cortisol levels (Source notes this concern, particularly at higher doses.) +6 więcej Elevated prolactin levels (Source notes this concern, particularly at higher doses.) Flushing (Reported by source; severity not quantified.) Nausea (Reported by source; severity not quantified.) Headache (Reported by source; severity not quantified.) Possible histamine release (Source advises caution for MCAS or histamine sensitivity, but does not quantify risk.) Limited long-term safety data (Source indicates long-term safety evidence is limited.)
Podsumowanie researchu	The source separates Hexarelin's evidence into endocrine and cardiovascular areas. It describes older human endocrine research as supporting growth hormone release. For cardiac protection, the source points mainly to preclinical evidence: a 2002 Circulation Research mechanism paper identifying CD36 as a cardiac receptor for growth hormone-releasing peptides, rodent studies reporting improved left ventricular function and cardiomyocyte protection during ischemia-reperfusion injury, and one 2017 finding involving interleukin-1 signaling. It also cites 2014 and 2017 reviews discussing the cardioprotective hypothesis. The same source cautions that large modern human trials have not shown Hexarelin treats or prevents heart disease, and it notes rapid tolerance with continued exposure as the GH response fades.	The supplied source describes GHRP-6 as a research tool studied in humans, mainly for laboratory or diagnostic investigation of growth hormone release rather than as a validated therapeutic intervention. It notes early research showing growth hormone release, and connects investigation of this peptide class to the later identification of ghrelin. A cited 2013 pharmacokinetic study in nine healthy men is summarized as finding very low oral bioavailability and an elimination half-life of about 2.5 hours. The source states that popular fitness-related outcome claims such as muscle gain, fat loss, and healing lack controlled human outcome-trial support, and it reiterates that GHRP-6 is not FDA or EMA approved.
Referencje	Peptibase peptides Peptibase peptides +2 więcej Peptibase peptides Peptibase peptides	Źródło Źródło +1 więcej Źródło
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

Hexarelin

GHRP-6

Kategoria

Hormon wzrostu

Znany tez jako

Examorelin, HEX

Growth Hormone Releasing Peptide 6, SKF-110679

Zatwierdzony przez FDA

Nie

Status kliniczny

Investigational; clinical trials conducted

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Preclinical/investigational; source notes FDA Category 2 compounding restriction concerns

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

GH release, cardiac protection, muscle growth

Appetite stimulation, muscle building, GH release

Jak dziala

Hexarelin is reported to work through GHS-R1a and CD36. GHS-R1a, also known as the ghrelin receptor, is the pituitary-linked pathway associated with growth hormone release. CD36 is described in the source as a receptor present on cardiac muscle cells and small blood vessels; preclinical work links this pathway to coronary-flow changes and protection from ischemia-reperfusion injury. The source notes that cardiac effects were still seen in growth-hormone-deficient animals, suggesting the cardiac mechanism is not simply downstream of growth hormone release.

GHRP-6 is reported to act as an agonist at GHS-R1a, the growth hormone secretagogue receptor associated with ghrelin biology. The source links receptor activation in pituitary and hypothalamic pathways to growth hormone pulse release. It also notes that GHS-R1a involvement in NPY/AgRP appetite circuitry may contribute to GHRP-6's prominent hunger effect, and that higher doses may raise cortisol and prolactin.

Typowe dawkowanie

100-200 mcg 2-3x daily · 2-3x daily

100-300 mcg 2-3x daily · 2-3x daily · Subcutaneous injection

Dawkowanie z badań

100-200 mcg per injection · 4-8 weeks (desensitization occurs) · Subcutaneous injection

100-300 mcg per injection · 8-12 weeks · Subcutaneous injection, reported as fasted

Typowy czas trwania

4-8 weeks (desensitization occurs)

8-12 weeks

Podanie

Subcutaneous injection

Subcutaneous injection, reported with fasted timing

Timing

Morning and before bed, fasted

Empty stomach

Reported timing: fasted morning use or before bed

Source reports empty-stomach or fasted timing

Poziom dowodów

Badania kliniczne

Mozliwe skutki uboczne

Increased appetite
Water retention
Tingling or numbness

+5 więcej

Elevated cortisol and prolactin
Flushing
Headache
May trigger histamine release (Source advises caution with MCAS or histamine sensitivity.)
Receptor desensitization with continuous use (Source notes desensitization and fading GH response with continued use.)

Significant hunger increase (Source describes this as especially pronounced among GHRPs.)
Water retention (Reported by source; severity not quantified.)
Elevated cortisol levels (Source notes this concern, particularly at higher doses.)

+6 więcej

Elevated prolactin levels (Source notes this concern, particularly at higher doses.)
Flushing (Reported by source; severity not quantified.)
Nausea (Reported by source; severity not quantified.)
Headache (Reported by source; severity not quantified.)
Possible histamine release (Source advises caution for MCAS or histamine sensitivity, but does not quantify risk.)
Limited long-term safety data (Source indicates long-term safety evidence is limited.)

Podsumowanie researchu

The source separates Hexarelin's evidence into endocrine and cardiovascular areas. It describes older human endocrine research as supporting growth hormone release. For cardiac protection, the source points mainly to preclinical evidence: a 2002 Circulation Research mechanism paper identifying CD36 as a cardiac receptor for growth hormone-releasing peptides, rodent studies reporting improved left ventricular function and cardiomyocyte protection during ischemia-reperfusion injury, and one 2017 finding involving interleukin-1 signaling. It also cites 2014 and 2017 reviews discussing the cardioprotective hypothesis. The same source cautions that large modern human trials have not shown Hexarelin treats or prevents heart disease, and it notes rapid tolerance with continued exposure as the GH response fades.

The supplied source describes GHRP-6 as a research tool studied in humans, mainly for laboratory or diagnostic investigation of growth hormone release rather than as a validated therapeutic intervention. It notes early research showing growth hormone release, and connects investigation of this peptide class to the later identification of ghrelin. A cited 2013 pharmacokinetic study in nine healthy men is summarized as finding very low oral bioavailability and an elimination half-life of about 2.5 hours. The source states that popular fitness-related outcome claims such as muscle gain, fat loss, and healing lack controlled human outcome-trial support, and it reiterates that GHRP-6 is not FDA or EMA approved.

Referencje

Peptibase peptides Peptibase peptides

+2 więcej

Peptibase peptides Peptibase peptides

Źródło Źródło

+1 więcej

Źródło

Pełny profil

Zobacz szczegóły